Howard H. Bailey, MD Print Friendly PageFaculty, University of Wisconsin School of Medicine and Public Health
Dr. Bailey is the Director of the University of Wisconsin Carbone Cancer Center and a professor of Medicine at the UW School of Medicine and Public Health. Dr. Bailey's clinical expertise is in sarcomas and gynecologic malignancies and his research focus is in anti-cancer drug development, especially chemoprevention, and research network development. He graduated from medical school at the University of North Dakota and completed his internship and residency at Southwestern Michigan Area Health Education Center in Kalamazoo. He completed a fellowship in Medical Oncology at the University of Wisconsin and completed a Research Fellowship at the UW Carbone Cancer Center. Dr. Bailey is board certified in Internal Medicine and Medical Oncology.
Dr. Bailey is the principal investigator of the UW Chemoprevention Consortium, an NCI-sponsored research network of Universities that conduct Phase I and II clinical trials for chemopreventive agents. Dr. Bailey also leads the UWCCC Chemoprevention Scientific Program and Chemoprevention Disease Orientated Work Group. He is the senior leader and advisory committee chair for the Wisconsin Network for Health Research, a collaborative effort across the state to promote greater inter-institutional cooperation in research and to move research results to the bedside more efficiently and effectively. Dr. Bailey was appointed to the national committee which reviews all NCI-designated Cancer Centers in 2011.
Dr. Bailey is the University's expert on drug and nutrient development for the prevention or treatment of cancer and a national expert on chemoprevention. Cancer chemoprevention is the use of natural, synthetic (made in a laboratory) or biologic (form a living source) substances to reverse, suppress or prevent the development of cancer. He is internationally recognized as an expert in chemoprevention and sarcoma and has lectured both in the United States and abroad. Dr. Bailey has directed or participated in more than 100 cancer clinical trials examining agents for prevention or treatment of cancer.
UW Health Clinics
UW School of Medicine and Public Health
|Department of Medicine|
Professional Certifications and Education
UW Comprehensive Cancer Center
Southwestern Michigan Area Health Education Center, Kalamazoo
Southwestern Michigan Area Health Education Center, Kalamazoo
University of North Dakota, 1985
|Medical interpreters are available to help patients communicate with hospital and clinic staff. For more information, please contact interpreter services at (608) 262-9000.|
Dr. Bailey is involved in the research of new clinical agents for the prevention and treatment of cancer. He leads the Etiology and Chemoprevention Program of the UW Carbone Cancer Center - which examines the causes of cancer and then translates this knowledge to develop and evaluate drugs, vitamins, or other agents to try to reduce the risk of or delay the development of cancer. He is the principal investigator of the Chemoprevention Consortium - a consortium of five national institutions to conduct multiple Phase I and II clinical trials for chemopreventive agents.
Gee JR Saltzstein DR Messing E Kim K Kolesar J Huang W Havighurst TC Harris L Wollmer BW Jarrard D House M Parnes H Bailey HH .
Phase Ib placebo-controlled, tissue biomarker trial of diindolylmethane (BR-DIMNG) in patients with prostate cancer who are undergoing prostatectomy. Eur J Cancer Prev. 2016 Jul;25(4):312-20
[PubMed ID: 26313229]
Bailey HH Chuang LT duPont NC Eng C Foxhall LE Merrill JK Wollins DS Blanke CD .
American Society of Clinical Oncology Statement: Human Papillomavirus Vaccination for Cancer Prevention. J Clin Oncol. 2016 May 20;34(15):1803-12
[PubMed ID: 27069078]
Fabian CJ Kimler BF Zalles CM Phillips TA Metheny T Petroff BK Havighurst TC Kim K Bailey HH Heckman-Stoddard BM .
Clinical Trial of Acolbifene in Premenopausal Women at High Risk for Breast Cancer. Cancer Prev Res (Phila). 2015 Dec;8(12):1146-55
[PubMed ID: 26391916]
Wisinski KB Ledesma WM Kolesar J Wilding G Liu G Douglas J Traynor AM Albertini M Mulkerin D Bailey HH .
A phase I study to determine the maximum tolerated dose and safety of oral LR-103 (1α,24(S)Dihydroxyvitamin D2) in patients with advanced cancer. J Oncol Pharm Pract. 2015 Dec;21(6):416-24
[PubMed ID: 24986793]
Anderson CP Matthay KK Perentesis JP Neglia JP Bailey HH Villablanca JG Groshen S Hasenauer B Maris JM Seeger RC Reynolds CP .
Pilot study of intravenous melphalan combined with continuous infusion L-S,R-buthionine sulfoximine for children with recurrent neuroblastoma. Pediatr Blood Cancer. 2015 Oct;62(10):1739-46
[PubMed ID: 26153194]
Kolesar JM Pomplun M Havighurst T Stublaski J Wollmer B Kim K Tangrea JA Parnes HL House MG Gee J Messing E Bailey HH .
Soy food frequency questionnaire does not correlate with baseline isoflavone levels in patients with bladder cancer. J Oncol Pharm Pract. 2015 Apr;21(2):128-31
[PubMed ID: 24642450]
Masters GA Krilov L Bailey HH Brose MS Burstein H Diller LR Dizon DS Fine HA Kalemkerian GP Moasser M Neuss MN O'Day SJ Odenike O Ryan CJ Schilsky RL Schwartz GK Venook AP Wong SL Patel JD .
Clinical cancer advances 2015: Annual report on progress against cancer from the American Society of Clinical Oncology. J Clin Oncol. 2015 Mar 1;33(7):786-809
[PubMed ID: 25605863]
Agger WA Siddiqui D Lovrich SD Callister SM Borgert AJ Merkitch KW Mason TC Baumgardner DJ Burmester JK Shukla SK Welter JD Stewart KS Washburn MJ Bailey HH .
Epidemiologic factors and urogenital infections associated with preterm birth in a midwestern U.S. population. Obstet Gynecol. 2014 Nov;124(5):969-77
[PubMed ID: 25437726]
Adhami VM Bailey HH Mukhtar H .
Cancer chemoprevention is not a failure. Carcinogenesis. 2014 Sep;35(9):2154-5
[PubMed ID: 24970761]
Deming DA Ninan J Bailey HH Kolesar JM Eickhoff J Reid JM Ames MM McGovern RM Alberti D Marnocha R Espinoza-Delgado I Wright J Wilding G Schelman WR .
A Phase I study of intermittently dosed vorinostat in combination with bortezomib in patients with advanced solid tumors. Invest New Drugs. 2014 Apr;32(2):323-9
[PubMed ID: 24114123]
Schelman WR Traynor AM Holen KD Kolesar JM Attia S Hoang T Eickhoff J Jiang Z Alberti D Marnocha R Reid JM Ames MM McGovern RM Espinoza-Delgado I Wright JJ Wilding G Bailey HH .
A phase I study of vorinostat in combination with bortezomib in patients with advanced malignancies. Invest New Drugs. 2013 Dec;31(6):1539-46
[PubMed ID: 24114121]
Kolesar JM Traynor AM Holen KD Hoang T Seo S Kim K Alberti D Espinoza-Delgado I Wright JJ Wilding G Bailey HH Schelman WR .
Vorinostat in combination with bortezomib in patients with advanced malignancies directly alters transcription of target genes. Cancer Chemother Pharmacol. 2013 Sep;72(3):661-7
[PubMed ID: 23903894]
Wisinski KB Faerber A Wagner S Havighurst TC McElroy JA Kim K Bailey HH .
Predictors of willingness to participate in window-of-opportunity breast trials. Clin Med Res. 2013 Sep;11(3):107-12
[PubMed ID: 23580787]
Gee J Bailey H Kim K Kolesar J Havighurst T Tutsch KD See W Cohen MB Street N Levan L Jarrard D Wilding G .
Phase II open label, multi-center clinical trial of modulation of intermediate endpoint biomarkers by 1α-hydroxyvitamin D2 in patients with clinically localized prostate cancer and high grade pin. Prostate. 2013 Jun;73(9):970-8
[PubMed ID: 23335089]
Bailey HH Mukhtar H .
Green tea polyphenols and cancer chemoprevention of genitourinary cancer. Am Soc Clin Oncol Educ Book. 2013;:92-6
[PubMed ID: 23714466]
Rocque GB Barnett AE Illig LC Eickhoff JC Bailey HH Campbell TC Stewart JA Cleary JF .
Inpatient hospitalization of oncology patients: are we missing an opportunity for end-of-life care? J Oncol Pract. 2013 Jan;9(1):51-4
[PubMed ID: 23633971]
Kreul SM Havighurst T Kim K Mendonça EA Wood GS Snow S Borich A Verma A Bailey HH .
A phase III skin cancer chemoprevention study of DFMO: long-term follow-up of skin cancer events and toxicity. Cancer Prev Res (Phila). 2012 Dec;5(12):1368-74
[PubMed ID: 23060038]
Tevaarwerk A Wilding G Eickhoff J Chappell R Sidor C Arnott J Bailey H Schelman W Liu G .
Phase I study of continuous MKC-1 in patients with advanced or metastatic solid malignancies using the modified Time-to-Event Continual Reassessment Method (TITE-CRM) dose escalation design. Invest New Drugs. 2012 Jun;30(3):1039-45
[PubMed ID: 21225315]
Kenkre VP Long WL Eickhoff JC Blank JH McFarland TA Bottner W Rezazedeh H Werndli JE Bailey HH Kahl BS .
Maintenance rituximab following induction chemo-immunotherapy for mantle cell lymphoma: long-term follow-up of a pilot study from the Wisconsin Oncology Network. Leuk Lymphoma. 2011 Sep;52(9):1675-80
[PubMed ID: 21864042]
Traynor AM Thomas JP Ramanathan RK Mody TD Alberti D Wilding G Bailey HH .
Phase I trial of motexafin gadolinium and doxorubicin in the treatment of advanced malignancies. Invest New Drugs. 2011 Apr;29(2):316-22
[PubMed ID: 19997959]